Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens

Authors:
  • NTN. Thatcher
    N. Thatcher
  • ACA. Chang
    A. Chang
  • PPP. Parikh
    P. Parikh
  • KPK. Pemberton
    K. Pemberton
  • VAV. Archer
    V. Archer
Publisher website
Google Scholar
Abstract
No abstract available